Open access
Open access
Powered by Google Translator Translator

RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.

8 Sep, 2022 | 14:24h | UTC

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.